Leighton, a child RYLAZE patient, spending time with her father

“When we learned a clinical trial [completed 2021] was an option after Leighton's allergic reaction [to E. coli-derived asparaginase therapy], I was so happy. That meant there was another avenue to make sure Leighton could get the asparaginase therapy her little body needed.”
- Leighton’s Father (Actual Patient Family)

What makes RYLAZE different

After an allergic reaction to asparaginase derived from E. coli

Continue the treatment journey with RYLAZE

RYLAZE is the only Erwinia asparaginase approved by the Food and Drug Administration to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients who have had an allergic reaction to asparaginase derived from E. coli.

RYLAZE is a prescription medicine that is part of a multi-agent chemotherapy regimen used to treat adults and children 1 month or older who have ALL or LBL after an allergic reaction to E. coli asparaginase.

RYLAZE: When a different type of asparaginase is needed

Allergic reactions are a sign that an asparaginase therapy isn't working as it should.

After an allergic reaction to asparaginase derived from E. coli, the doctor may switch to RYLAZE so treatment can continue as intended.

RYLAZE works in the body like other asparaginase therapies, but it is derived from Erwinia chrysanthemi instead of E. coli.

Like other asparaginase therapies, RYLAZE may cause allergic reactions. Seek medical advice immediately if symptoms of an allergic reaction occur.

What is RYLAZE?

RYLAZE is a prescription medicine, given by intramuscular injection, that is part of a chemotherapy regimen used to treat adults and children 1 month or older who have acute lymphoblastic leukemia (ALL), a type of blood cancer that affects the white blood cells that help fight infection, and lymphoblastic lymphoma (LBL), a type of non-Hodgkin lymphoma that also affects white blood cells. RYLAZE is used in patients who have had an allergic reaction to E. coli asparaginase.

IMPORTANT SAFETY INFORMATION

RYLAZE should not be given to people who have had:

Serious allergic reactions to RYLAZE
Serious swelling of the pancreas (stomach pain), serious blood clots, or serious bleeding during previous asparaginase treatment

RYLAZE may cause serious side effects, including:

Allergic reactions (a feeling of tightness in your throat, unusual swelling/redness in your throat and/or tongue, rash, or trouble breathing), some of which may be life-threatening
Swelling of the pancreas (stomach pain), which, if left untreated, may be fatal
Blood clots (may be experienced as headache, arm or leg swelling, shortness of breath, or chest pain), which may be life-threatening
Bleeding, which may be life-threatening
Liver problems

Contact your doctor immediately if any of these side effects occur.

Some of the most common side effects with RYLAZE include:

Liver problems
Nausea and vomiting
Bone and muscle pain
Infection
Tiredness
Headache
Fever with low white blood cell count
Fever
Bleeding
Mouth swelling (sometimes with sores)
Pain in the abdomen
Decreased appetite
Allergic reactions
High blood sugar levels
Diarrhea
Swelling of the pancreas
Low levels of potassium in your blood

RYLAZE can harm your unborn baby. Inform your doctor if you are pregnant, planning to become pregnant, or nursing. Females of reproductive potential should use effective contraception (other than hormonal contraceptives) during treatment and for 3 months following the final dose. Do not breastfeed while receiving RYLAZE and for 1 week after the final dose.

Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.

These are not all the possible side effects of RYLAZE. For more information, ask your healthcare provider.

Call your doctor for medical advice about any side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).

Please see full Prescribing Information and discuss with your doctor.